Off to the Races: The FAA Initiates Informal Drone Rulemaking
Client Alert | 1 min read | 02.14.19
Yesterday, the Federal Aviation Administration (FAA) posted in the Federal Register the Notice of Proposed Rulemaking for Operations of Small Unmanned Aircraft Systems over People and the Advanced Notice of Proposed Rulemaking for Safe and Secure Operations of Small Unmanned Aircraft Systems. The substance and implications of the draft rules were explored in previous client alerts and can be accessed here and here. Comments to both notices are due April 15, 2019.
The FAA also issued an interim final rule requiring small drone owners to display their FAA-issued registration number on the exterior of the aircraft. This is a change from the current rule, which only requires that the number be readily accessible and readable at a close distance. Under the new rule, owners will no longer have the flexibility to place the number in an enclosed compartment on the device, a practice which “presents an imminent risk of harm to first responders,” according to the rule. The rule is effective February 25, 2019, without the usual notice and comment period. This immediate implementation further underscores the Government’s concern over the unique security risks posed by small drones. Interested parties should submit comments by March 15, 2019, as the rule may be amended based on comments received.
Insights
Client Alert | 5 min read | 01.27.25
After Trump Executive Orders, FDA Removes Diversity Guidance From Website
Days after President Trump issued an executive order (EO) taking aim at diversity, equity, and inclusion (DEI) programs and prohibiting federal recognition of gender identity apart from biological sex, previously issued draft guidance on diversity in clinical trials was removed from the website of the U.S. Food and Drug Administration (FDA). While the removed guidance was in draft form, it is highly unusual for FDA to revoke or alter draft guidance without issuing a statement or further guidance. This move raises questions about the applicability of statutory obligations to submit clinical trial Diversity Action Plans and the agency’s current thinking on best practices for clinical development.
Client Alert | 8 min read | 01.27.25
Client Alert | 5 min read | 01.27.25
Client Alert | 2 min read | 01.27.25
State Department Pauses Almost All Foreign Assistance Funding